Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06518148

Causes of Visual Impairment Among Patients Applying for the Visually Disability Certification

Causes of Visual Impairment Among Patients Applying for the Visually Disability Certification in Upper Egypt: A Retrospective Study

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

Assiut University

Asyut, 33033, Egypt

About this study

There are at least 2.2 billion individuals with near- or far-sightedness worldwide. Nearly half of these cases-at At least 1 billion-have untreated vision impairment that may have been avoided. The leading cause of blindness or impaired distant vision among these 1 billion people is diabetic retinopathy (3.9 million), age-related macular degeneration (8 million), cataracts (94 million), refractive error (88.4 million), and glaucoma (7.7 million). Presbyopia (826 million) is the primary ailment that impairs close vision.

According to estimates, there are four times as many cases of distant vision impairment in low- and middle-income areas as there are in high-income areas.

Aging populations and population expansion are predicted to raise the likelihood that more people may have visual impairment. Early on, irreversible severe visual impairment in young children can lead to delayed motor, verbal, emotional, social, and cognitive development, which can have long-term effects. Children of school age who are visually impaired may also perform less academically. The quality of life is significantly impacted by vision impairment in adult populations. Adults who are visually impaired may have greater rates of anxiety and depression as well as decreased employment rates.

Vision impairment in older persons can increase their risk of falling and breaking bones, walking difficulties, social isolation, and early admission into nursing homes or other care facilities.

According to estimates, vision impairment costs the world's economy $411 billion annually in lost productivity (purchasing power parity) . This amount is greatly above the predicted $25 billion cost gap incurred from treating vision impairment.

This study is to demonstrate the causes of visual impairment in upper Egypt among the different age groups and evaluate the possibility of preventing these disorders

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All patients referred to The Ministry of Social Solidarity with visual Disability in upper Egypt who were examined in the visual disability screening program from 2020-2024.

Exclusion criteria

  • The patients who had decreased vision but did not fit with the WHO definition of visual disability.

Treatment and study plan

1- uncorrected and best corrected visual acuity (UCVA and BCVA) by Snellen's-chart.2-slit lamp bio microscopy (Haag-Streit, USA).3-IOP measurements (Goldmann Applanation tonometer)

Diagnostic Test

diagnostic test;UCVA, IOP, Electrophysiological study

Other names: 3-fundus examination (+90D lens and indirect ophthalmoscope)., 4- Electrophysiological study visual evoked potential (VEP) and full filed electroretinogram (Metrovision machine).

Primary outcomes

  1. The relative frequencies or prevalence of different eye diseases/conditions causing visual disability

    Time frame: 10 month

  2. 2-Ranking of the leading cause(s) of visual impairment

    Time frame: 10 month

Sponsors and collaborators

Lead sponsor

New Valley University

Other

Collaborators

  • Assiut University

Registry information

Official study title

Causes of Visual Impairment Among Patients Applying for the Visually Disability Certification in Upper Egypt: A Retrospective Study

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Jul 24, 2024
Registry last updated
Sep 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.